key: cord-0832620-rim8yigg
authors: Katz, Micah; Newmark, Rebecca L.; Aronstam, Alison; O'Grady, Niamh; Strome, Sara; Rafie, Sally; Karlin, Jennifer
title: An implementation project to expand access to self-administered Depot Medroxyprogesterone Acetate (DMPA)
date: 2020-09-12
journal: Contraception
DOI: 10.1016/j.contraception.2020.09.001
sha: 7f8b32ff386851dfe47e18a44f4e02d26a0d1af2
doc_id: 832620
cord_uid: rim8yigg

OBJECTIVE: To describe the implementation and results of a proactive patient outreach project to offer self-administered, depot medroxyprogesterone (DMPA) subcutaneous (SC) to interested patients at a California safety-net clinic following expanded state Medicaid coverage. STUDY DESIGN: We contacted non-pregnant patients at an urban, safety-net hospital-based primary care clinic who had been prescribed DMPA intramuscular (IM) in the past year to gauge interest in self-administered DMPA-SC. Interested patients received a prescription for DMPA-SC and a telehealth appointment with a clinic provider to learn self-injection. We recorded patient interest in DMPA-SC, completed appointments, and completed first injections. We conducted initial outreach in May, 2020 and recorded appointment attendance and completed injections through August, 2020. RESULTS: Of 90 eligible patients (age 17-54), we successfully contacted and discussed DMPA-SC with 70 (78%). Twenty-six (37%) patients expressed interest in DMPA-SC and scheduled telehealth appointments to learn to self-administer the medication. Fifteen (58%) of those interested (21% of the total) successfully self-injected DMPA-SC. Of the 44 (63%) patients not interested in DMPA-SC, the three most common reasons were fear of self-injection (n=23 [52%]), wanting to stop DMPA (n=11 [25%]), and satisfaction with DMPA-IM (n=6 [14%]). CONCLUSION: There is interest in and successful initiation of self-administered DMPA-SC among patients at an urban safety net hospital-based primary care clinic who have used DMPA-IM in the last year.

Depot medroxyprogesterone acetate (DMPA) is a progestin-only, injectable contraceptive administered every three months either intramuscularly (IM) or subcutaneously (SC). DMPA-SC and IM are equally safe and effective; however, DMPA-SC offers potential advantages over IM administration [1, 2] . DMPA-SC was initially designed with the possibility for self-administration, with a smaller needle and with one-third the volume of medication administered compared to DMPA-IM. In global settings, these differences in formulation and administration mechanism contribute to equal or reduced pain and side effects with DMPA-SC [2] [3] [4] [5] . Furthermore, selfadministration offers greater autonomy and reduced barriers to care by removing the necessity of returning to a clinic every three months. Global and US data potentially reflect these benefits, showing improved continuation rates of self-administered DMPA-SC relative to clinic administered DMPA-IM and DMPA-SC [5, 6] .

DMPA-SC has the potential to satisfy a significant interest in self-administered, reversible, injectable contraception in the US [7] . Currently, DMPA-SC is approved by the United States Food and Drug Administration (FDA) for administration by a healthcare professional only. Additionally, many public and private insurers either do not cover it as a pharmacy benefit or place utilization requirements like prior approval upon its use, creating barriers to access [8] .

Due to the novel Coronavirus 2019 (COVID-19) presenting emergent public health risks, the Centers for Medicare & Medicaid Services (CMS) issued waivers under section 1135 of the Social Security Act to facilitate local health departments' responses to the pandemic [9] . California's public health insurance program (Medi-Cal) utilized the 6 1135 waiver to approve DMPA-SC as a pharmacy benefit without prior approval as of April 2020 [10] . This change also extended to patients who receive their contraceptive coverage through California's Medicaid expansion program, Family Planning, Access, Care and Treatment (Family PACT), which provides comprehensive family planning services to eligible low income (under 200% federal poverty level) residents. Enabled by this policy change, we describe the initial implementation project aimed at offering selfadministered DMPA-SC to current or historical DMPA-IM users at an urban, California, primary care clinic. We include both the process of changing from clinic administered DMPA-IM to pharmacy supplied DMPA-SC as well as interest in DMPA-SC and success of first injection to offer insight to implementation in other settings.

Our population included all non-pregnant patients who received DMPA-IM for contraception within the prior 9 months at an urban, hospital-based safety-net primary care clinic in San Francisco. Almost all the patients who receive care at our clinic are eligible for Medi-Cal or Family PACT.

We searched our electronic health record (EHR) for patients who received DMPA-IM from August 2019 to May 2020, with August 2019 corresponding to our transition to EHR. We developed a patient-centered contraceptive counseling script (online Appendix A) to call patients and assess their interest in self-administered DMPA-SC. In May 2020 (approximately one and a half months after the implementation of city and state-wide shelter-in-place orders), a team of five medical and pharmacy students contacted these patients and offered the DMPA-SC formulation. We used phone interpreters for non-English speaking patients and called all patients a maximum of three times without receiving a response before leaving a general voice message with clinic contact information.

Upon reaching patients, we confirmed their identity with name and date of birth and verified past or present DMPA-IM use. We then described the new availability of DMPA-SC and its similarities and differences from DMPA-IM, after which we asked about interest in use of this method. For patients interested in DMPA-SC, we ordered prescriptions to their pharmacy of choice and scheduled telehealth appointments with a provider at the clinic (their primary care physician, resident or attending physician, pharmacist, or advanced care practitioner) to teach them how to self-inject. Additionally, we instructed those interested patients more than 15 weeks from the last DMPA injection and who had been sexually active to perform a home urine pregnancy test prior to DMPA-SC injection. We instructed patients who had been sexually active within two weeks prior to DMPA-SC injection to repeat pregnancy testing two weeks after their injection (and four weeks after the sexual encounter). If the patient could not afford an at home pregnancy test, we offered the option to come to the clinic for a point-of-care pregnancy test that would be paid for by their insurance.

Providers performed telehealth appointments using video or telephone, depending on patient preference. They discussed the differences between DMPA-SC and DMPA-IM and instructed patients how to administer the injection and dispose of the needle. Providers had access to the materials in Appendix B for their own education and to share with patients. We offered observed first injection during the telehealth visit but did not require it. If the patient planned on having a family member or community healthcare worker (HCW) administer the injection, we recommended, but did not require, that person to attend the telehealth visit. If patients injected DMPA-SC at a date later than their appointment, we followed up to confirm successful injection for the purposes of data collection; however, it was not a part of the provider workflow. We reached out to patients who missed their appointments for follow up. If we could not reach the patient for follow up, we monitored their EHR to check for new appointments and contraception use. We collected data on appointments and injections that occurred through August 2020. provider. If the patients' insurer rejected the prescription claim at the pharmacy, a pharmacist or pharmacy student contacted the pharmacy to provide information and guide them through successfully processing the prescription claim through insurance.

We collected this data as part of outreach to facilitate routine care to provide patients with increased contraceptive options in the context of a pandemic. The Institutional Review Board at University of California San Francisco reviewed our plan and provided exempt status for our study.

Of the 90 patients who fit our criteria, we successfully contacted 72 (80%), 70 (97%) of whom were willing to speak to us about their birth control. Table 1 depicts the characteristics of our study cohort. Figure 1 presents the number of patients who expressed interest in DMPA-SC, those who went on to successfully inject DMPA-SC, and the contraceptive outcomes of those who did not take up DMPA-SC.

Of the 70 patients we contacted, 26 (37%) expressed initial interest in DMPA-SC.

While we did not ask patients why they were interested in DMPA-SC as a part of our data collection, many spontaneously offered their motivations. Some patients cited the extenuating circumstances of COVID-19 as an influence to start self-administration of the subcutaneous formulation. Patients commonly expressed that they had cancelled, or were planning to cancel, their DMPA-IM appointments because of COVID-19 and were grateful for another method of DMPA administration that did not require entering a Fifteen patients (21% of those contacted and 58% of those interested in DMPA-SC) successfully injected. Five patients had a friend, family member or community HCW provide the injection. Of the 26 patients interested in DMPA-SC, 11 (42%) did not initiate. When we followed up with these patients about the reasons that they did not complete the injection, they cited a multitude of intertwining factors including changing their mind about self-injection, moving home location, a desire to stop all birth control, clinic miscommunication, and pharmacy and insurance delays.

Over one-third of patients who currently or recently used DMPA-IM at an urban, hospital-based primary care clinic expressed interest in home-administered DMPA-SC in the context of state and local shelter-in-place orders and other social distancing guidelines in response to COVID-19. Those who declined DMPA-SC primarily cited an aversion to self-injection, satisfaction with DMPA-IM, or a desire to stop all DMPA.

Many, but not all, cited COVID-19 as a motivating factor to switch to home-administered DMPA-SC. This interest in home-administered, injectable contraception in a safety-net setting is consistent with prior studies demonstrating interest in self-injectable contraception for the general population. One multi-site survey of family planning clinics and abortion clinics in the US found that 21% of participants expressed interest in selfadministered injectable contraception, with greater interest among those who faced increased barriers to care [7] . Multiple factors might explain our higher initial interest rate. As our sample population contained only current or past users of DMPA-IM, our population may have been more likely to consider an injectable method of contraception and the specific side effects of DMPA acceptable. Additionally, we conducted our project during a peak in COVID-19 infections, with many of our patients citing the pandemic as a barrier to accessing clinical care.

In addition to interest, our data indicate appreciable uptake of home-administered DMPA. We believe this success was due to the person-centered approach we employed in offering this recently-covered contraceptive method in the context of COVID-19 related barriers to accessing clinical care. Additionally, supporting administration by a family or community member seemed to contribute to successful initiation. This is consistent with other studies examining the acceptability of DMPA-SC in the global setting, which included administration by a community member as an option to facilitate contraceptive accessibility and patient comfort [4, 5] . Future DMPA-SC implementation efforts might mention community member administration to prospective patients more uniformly during outreach and contraceptive counseling.

Patients who expressed initial interest, but did not successfully inject DMPA-SC, encountered barriers to receiving their teaching at the telehealth visit or obtaining their medications due to clinic miscommunication, prior approval requirements, or losing health insurance entirely. In some cases, patients were unable to obtain their prescription from their pharmacy without direct advocacy from our team. These logistical If it is about side effects (not pain or coming into clinic): I am so sorry to hear that you are experiencing _______. Would you like me to schedule an appointment with a provider so that you can discuss ways to manage _____ or discuss switching to another method?

If yes: I will send a message to the front desk and they will schedule a telephone appointment with a provider. You should hear from them shortly. Is there anything else I can do for you today?

If it is about the side effects of either pain of injection or coming into clinic: Thank you for sharing that with me. I hear that you do not like (either: the pain with injections or coming into clinic). Actually, the reason why I was calling is because there may be another option for you that is the same medicine as the depo-provera injection that you get now but that does not require you to come into clinic to get an injection in your muscle. Can I tell you more about that?

If patient says no, or does not want to talk about it: No problem! I want you to know that we are here for you. Would you like me to schedule an appointment with a provider so that you can discuss other methods or ways to manage the problems you have with your contraceptive method?

If no: No problem! I see that you have an appointment on XX date for an IM injection of depo-provera. Would you like me to cancel that appointment for you? Also, I would like you to know that we are here for you at any time if you would like to discuss contraception or anything else. Our number is XXX-XXX-XXXX If yes, First, I wanted to confirm if you are still using and planning to continue depo-provera for contraception?

If yes: Great! So, right now, you come into the clinic and get an injection into your arm every 15 weeks. This is called an intra-muscular injection. There is actually an option that is now available that would allow you to give yourself an injection with a smaller needle into your skin every 14 weeks at home. This is called a subcutaneous injection.

This option is paid for by your insurance because of the COVID pandemic since it allows people have the same medicine to prevent pregnancy but they can give it to themselves in their own home. This lowers the risk of contracting COVID from coming into the clinic. Besides this benefit during COVID, many people really like this form of the medicine because they can do it from the privacy of their own home and they do not have to go into the clinic, it is a smaller needle that is injected into the skin so for some it is less painful than the larger needle when you come to clinic, and there is a little bit less medicine in this form and so some people experience less side effects.

Is this something you would be interested in doing by yourself?

If yes: Great! You have an appointment with a provider to teach you how to do the injection yourself. At that appointment, you will have your medication and will inject it yourself with the support of the provider on the phone. Your appointment will be between 1-5pm on XXX date (Monday before 14 weeks since their last IM depo). Thank you for sharing that information with me. Again, your appointment is ____. We will see you then. If you need anything before then, please call the clinic at XXX-XXX-XXXX.

If yes: you can go to the following websites to learn more:

If interested in learning more about how to set reminder, can discuss with patient: You can also go to the bedsider app to download a reminder calendar. Go to the app store, "Get" Bedsider Birth Control (blue app with a clock and BR in center). When it opens, choose, "send me notifications." Then, go to the bottom to "create new reminder". Otherwise: Thank you. Great! A scheduler will reach out to schedule your telephone appointment with a provider to discuss how to use SQ depo! 20 Appendix B: Educational materials provided to clinicians who had telehealth appointments with patients switching from DMPA-IM to self-administered DMPA-SC 1) Good candidates for self-injection of subcutaneous DMPA (DMPA-SC) include patients who are experienced in self-injection of other drugs (such as medications to induce ovulation for IVF, insulin, or drugs for multiple sclerosis), but it can be used by anyone. Use clinical judgement to determine whether appropriate for a specific patient and document in the decision. Discuss that this is off-label use because the FDA has only approved DMPA-SC for provider administration. However, DMPA-SC has been shown to have the same effectiveness if administered by a provider or by self-administration. 2) In preparation for your counseling appointment, the patient has been sent a prescription to their pharmacy of choice for DMPA-SC (104 mg/0.65 mL) (NDC code 00009-4709-13) and alcohol pads q 3 months for 3 refills. We have instructed them to pick up the medications prior to your appointment so that they can inject at the time of the appointment if they desire. You can send additional refills at the time of the appointment or after 3 successful injections. 3) Contraindications and side effects are the same for DMPA-SC and DMPA-IM. 4) If greater than 15 weeks have passed since DMPA-IM, and patient has been sexually active, recommend pregnancy test. Patient can come to clinic for free POC pregnancy test or can purchase pregnancy test for $8-$15 at a pharmacy. 5) Consider whether a back-up method is needed: · If DMPA-SC started within 7 days of menstruation, no back up method needed. · If DMPA-SC started >7 days since menstruation, recommend barrier method or plan B for sexual intercourse within 7 days of starting, and recommend repeat pregnancy test. 6) For an informational video about DMPA-SC, see Bixby's Innovating Education in Reproductive Health video This is How I Teach DMPA-SC: https://www.innovating-education.org/2020/06/this-is-how-i-teach-self-injectiondmpa-sc/. 7) If patient wants a family member or friend to do the injection for them, offer teaching to that assistant. 8) Provide patient education about how to administer (can send patient education videos and written material for review prior to counseling appointment). This counseling can be done via telemedicine--telephone or in person--depending on how the patient learns best. 9) Consider scheduling a telehealth visit every 12 weeks if patient would like support. Evidence shows that patients' self-injection improves with continuation of method. Remind the patient that the first few injections may have site irritation or pain but will likely improve over time. 10)Counsel regarding disposal of needles: sharps containers may not be covered by insurance but patients can request at pharmacy. (See https://safeneedledisposal.org/ for information on safe needle disposing.)

Contraceptive efficacy and safety of DMPA-SC

Subcutaneous DMPA vs. intramuscular DMPA: A 2-year randomized study of contraceptive efficacy and bone mineral density

Changes in bleeding patterns with Depot Medroxyprogesterone Acetate Subcutaneous injection 104 Mg

Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal

Continuation of self-injected versus provideradministered contraception in Senegal: a nonrandomized, prospective cohort study

Self-administration of injectable contraception: a systematic review and meta-analysis

Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States

PROVERA 104 is sold by the Pfizer company. The package was introduced in 1959 and the package label was revised December

Section 1135 Flexibilities Requested in March 16

Information Regarding the Use of Subcutaneous Depot Medroxyprogesterone Acetate During the 2019 Novel Coronavirus Public Health Emergency n

Expectant management versus surgical evacuation in first trimester miscarriage: health-related quality of life in randomized and non-randomized patients

Provide information about safe storage of the medication. DMPA-SC should be stored at room temperature. Tell patients not to put in the refrigerator, freezer, or leave outside or in a car

If patient misses a dose: patient can take DMPA-SC anytime within 14 weeks since their last DMPA-SC and be covered. However, if there is more than 14 weeks since their last DMPA-SC, recommend giving it as soon as possible, use condoms for a week and use Plan B if has unprotected sex during missed window and 7 days after injection

multiple languages including English

 Spanish written patient guidelines for DMPA-SC self